论文部分内容阅读
目的探讨还原型谷胱甘肽联合重组人促红素治疗尿毒症贫血患者的有效性与安全性。方法选择2014年1月—2016年5月在郑州市第七人民医院诊治的尿毒症贫血患者84例作为研究对象,根据随机信封抽签原则分为观察组与对照组各42例,对照组给予血液透析与口服促红细胞生成素治疗,观察组在对照组治疗的基础上给予还原型谷胱甘肽治疗,两组均治疗观察12周。结果两组治疗期间都无严重并发症发生,治疗后观察组总有效率(97.6%)明显高于对照组(85.7%),差异有统计学意义(P<0.05)。观察组与对照组治疗后的血清尿酸(UA)值明显低于治疗前,而血清内生肌酐清除率(Ccr)明显高于治疗前,组内对比都有统计学意义(P<0.05);同时治疗后观察组的血清UA明显低于对照组,Ccr值明显高于对照组,差异有统计学意义(P<0.05)。观察组治疗后的血红细胞(RBC)与血红蛋白(Hb)值分别为(3.38±0.34)×1012/L和(94.55±4.92)g/L,而对照组分别为(2.56±0.38)×1012/L和(73.24±5.39)g/L,都明显高于治疗前(P<0.05),且观察组也明显高于对照组,差异有统计学意义(P<0.05)。结论还原型谷胱甘肽联合重组人促红素治疗尿毒症贫血患者可改善肾功能与贫血状态,提高治疗疗效,安全性好,有很好的应用推广价值。
Objective To investigate the efficacy and safety of reduced glutathione combined with recombinant human erythropoietin in patients with uremia and anemia. Methods 84 patients with uremic anemia diagnosed and treated in the Seventh People’s Hospital of Zhengzhou City from January 2014 to May 2016 were selected as the research objects. According to the principle of random enveloping, 42 cases were divided into observation group and control group, and the control group was given blood Dialysis and oral administration of erythropoietin. The observation group was treated with reduced glutathione on the basis of the control group. Both groups were treated for 12 weeks. Results There were no serious complications during the treatment. The total effective rate (97.6%) in the observation group was significantly higher than that in the control group (85.7%) after treatment (P <0.05). The serum uric acid (UA) in the observation group and the control group was significantly lower than that before treatment, while the serum creatinine clearance (Ccr) in the observation group and the control group was significantly higher than before treatment (P <0.05). After treatment, the serum UA in the observation group was significantly lower than that in the control group, and the Ccr value was significantly higher than that in the control group (P <0.05). The values of RBC and Hb in the observation group were (3.38 ± 0.34) × 1012 / L and (94.55 ± 4.92) g / L, respectively, while those in the control group were (2.56 ± 0.38) × 1012 / L and (73.24 ± 5.39) g / L, respectively, were significantly higher than before treatment (P <0.05), and the observation group was also significantly higher than the control group, the difference was statistically significant (P <0.05). Conclusion Reduced glutathione combined with recombinant human erythropoietin in patients with uremia and anemia can improve renal function and anemia, improve the curative effect, safety, and have a good application of the promotion value.